Condition: Breast Cancer · HER2-positive Breast Cancer · ER Positive Breast Cancer · Sponsor: Ruth O'Regan
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
This description comes directly from the study's public registry record.
Ruth O'Regan, MD · 608-265-9701 · ruth_oregan@urmc.rochester.edu
Amber Ryba · 317-634-5842 · aryba@hoosiercancer.org
Always discuss trial participation with your own doctor first.
| University of Illinois Cancer Center | Chicago, Illinois, United States | Recruiting |
| University of Rochester Medical Center | Rochester, New York, United States | Recruiting |
| Penn State Cancer Institute | Hershey, Pennsylvania, United States | Recruiting |
| University of Wisconsin | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04886531